Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Europe

- PMLiVE

EU’s first health report card – must do better

Report implies Europe must shift its focus to disease prevention

- PMLiVE

Patently unclear?

The challenge of protecting  biotech innovations

- PMLiVE

Exploring serious market access roadblocks for rare bleeding disorders

Ensuring that sufferers get the treatment they require

- PMLiVE

Moving times

Continuity and stability are vital when it comes to the EMA's relocation when it leaves London

EU flag

Europe’s cancer drug regulation is ‘broken’, claims study

Suggests EMA oncology approvals could lead to wasted funds and patient harm

- PMLiVE

AbbVie deal with Amgen sets biosimilar Humira launch dates

Agreement will see Europe access the drug over four years earlier than patients in the US

- PMLiVE

Macron, Merkel and May: implications of the 2017 elections for the life science industry

Political instability and policy continuity in Europe’s biggest economies mean a worsening commercial environment stacked with uncertainty

- PMLiVE

IMI aims €130m at medical research’s unanswered questions

Targets for the partnership’s latest funding round including Alzheimer’s

- PMLiVE

UK pharma launches legal challenge to NICE plans

Applies for judicial review of budget impact test

- PMLiVE

Digital disruption in market access

Infinite possibilities

- PMLiVE

Focus on value: A prescription for pharma

The pricing debate demands a common language to be developed

National Institute for Health and Care Excellence NICE logo

NICE agrees £20m cost ceiling for new drugs

New budget test set to begin from April and could delay uptake of new medicines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links